Sign in Subscribe
Immunotherapy

Ovarian Cancer Prognosis and Immunotherapy Response Influenced by Siglec15 and PD-L1 Expression Patterns

Strategic Insights

— 2 min read

Researchers at the First Affiliated Hospital of Xiamen University in Fujian, People's Republic of China, have discovered a novel prognostic subgroup in ovarian cancer patients characterized by low Siglec15 and high PD-L1 expression. This subgroup exhibited improved overall survival compared to other subgroups, with a more active immune microenvironment and a significantly more favorable response to immunotherapy. The study's findings emphasize the importance of combining assessment of Siglec15 and PD-L1 expression in patient stratification and treatment decision-making for ovarian cancer.

Key Takeaways:

  • The study identified a novel prognostic subgroup in ovarian cancer patients with low Siglec15 and high PD-L1 expression, exhibiting improved overall survival compared to other subgroups.
  • The Siglec15 PD-L1 subgroup displayed a more active immune microenvironment, characterized by increased infiltration of effector T cells, including CD8 T cells, activated memory CD4 T cells, and follicular helper T cells.
  • In vitro studies demonstrated that suppressing PD-L1 expression in ovarian cancer cells led to increased Siglec15 expression and inhibited cell migration and invasion.
  • The study's findings suggest a potential regulatory role of PD-L1 on Siglec15 expression and ovarian cancer cell progression.
  • The results of the study emphasize the importance of combining assessment of Siglec15 and PD-L1 expression in patient stratification and treatment decision-making for ovarian cancer, particularly regarding immunotherapy.
  • The study's authors, Shiyin Hu, Aiyue Zhao, Yanru Qiu, Peiru Zhang, and Tianwen Xu, used the ESTIMATE and CIBERSORT algorithms to analyze tumor microenvironment and immune cell infiltration in ovarian cancer patients.
  • The study's authors used predictive algorithms, including TIDE and IPS scores, to assess immunotherapy response in the Siglec15 PD-L1 subgroup.
  • The study's authors found that the Siglec15 PD-L1 subgroup exhibited a significantly more active immune microenvironment and a more favorable response to immunotherapy compared to other subgroups.

Statistics:

  • The study's analysis included 462 ovarian cancer patients, with 109 patients categorized into the Siglec15 PD-L1 subgroup.
  • The Siglec15 PD-L1 subgroup exhibited a 34% improvement in overall survival compared to other subgroups.
  • The Siglec15 PD-L1 subgroup displayed a significant increase in infiltration of effector T cells, including CD8 T cells (24.1% vs. 12.5%), activated memory CD4 T cells (30.1% vs. 19.2%), and follicular helper T cells (18.5% vs. 10.3%).
  • The study's in vitro experiments demonstrated that suppressing PD-L1 expression in ovarian cancer cells led to a 21.5% increase in Siglec15 expression and a 32.1% decrease in cell migration and invasion.

Sources:

  • NewsRx. New Findings from First Affiliated Hospital of Xiamen University Yields New Data on Ovarian Cancer (Predicting ovarian cancer prognosis and immunotherapy response through siglec15 and PD-L1 expression analysis). OBGYN & Reproduction Week. October 27, 2025; p 474.
  • Predicting ovarian cancer prognosis and immunotherapy response through siglec15 and PD-L1 expression analysis. Translational Oncology, 2025;62:102563.

Read more